UK markets closed

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0214+0.0194 (+1.94%)
At close: 05:13PM BST
Full screen
Previous close1.0020
Open1.0900
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.0200 - 1.0900
52-week range1.0200 - 1.0900
Volume2,200
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)2.12
PE ratio (TTM)N/A
EPS (TTM)-1.5480
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?

    CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Business Wire

    Syros to Present at JMP Securities Life Sciences Conference

    CAMBRIDGE, Mass., June 08, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 03, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).